Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

MRNS has been the subject of a number of other reports. HC Wainwright reiterated a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Down 0.2 %

MRNS opened at $0.55 on Friday. The firm has a 50-day moving average price of $0.52 and a 200-day moving average price of $0.82. Marinus Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $10.50. The company has a market capitalization of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several institutional investors have recently modified their holdings of MRNS. Virtu Financial LLC bought a new position in shares of Marinus Pharmaceuticals during the 4th quarter valued at $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in shares of Marinus Pharmaceuticals in the 4th quarter valued at about $54,000. World Investment Advisors LLC purchased a new stake in Marinus Pharmaceuticals during the 3rd quarter valued at about $104,000. Deltec Asset Management LLC bought a new position in Marinus Pharmaceuticals during the 4th quarter worth approximately $107,000. Finally, XTX Topco Ltd increased its stake in Marinus Pharmaceuticals by 1,564.7% in the 4th quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 206,614 shares during the period. 98.80% of the stock is currently owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.